Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines

Authors

  • Cinzia Dello Russo Dipartimento di Sicurezza e Bioetica, Sezione di Farmacologia, Università Cattolica Del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Department of Pharmacology & Therapeutics, Institute of Systems Molecular and Integrative Biology (ISMIB), University of Liverpool, Liverpool, United Kingdom https://orcid.org/0000-0002-2538-3832
  • Natalia Cappoli Dipartimento di Sicurezza e Bioetica, Sezione di Farmacologia, Università Cattolica Del Sacro Cuore, L.go F Vito 1, 00168 Rome, Italy; E-mail: natalia.cappoli@unicatt.it https://orcid.org/0000-0002-4705-3340
  • Elisabetta Tabolacci Dipartimento di Scienze Della Vita e Sanità Pubblica, Sezione di Medicina Genomica, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy https://orcid.org/0000-0002-4707-2242
  • Liliana Sollazzi Dipartimento di Scienze dell'Emergenza, Anestesiologiche e della Rianimazione, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy https://orcid.org/0000-0002-2973-6236
  • Pierluigi Navarra Dipartimento di Sicurezza e Bioetica, Sezione di Farmacologia, Università Cattolica Del Sacro Cuore, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy https://orcid.org/0000-0002-4424-650X
  • Paola Aceto Dipartimento di Scienze dell'Emergenza, Anestesiologiche e della Rianimazione, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Rome, Italy https://orcid.org/0000-0002-0228-0603

DOI:

https://doi.org/10.17179/excli2022-5667

Keywords:

human microglia, remifentanil, hyperalgesia, Interleukin-6, Interleukin-8, monocyte chemotactic protein 1

Abstract

Remifentanil is a potent ultra-short acting μ-opioid analgesic drug, frequently used in anaesthesia due to its favorable pharmacodynamic and pharmacokinetic profile. It may be associated with the occurrence of hyperalgesia. Preclinical studies suggest a potential role of microglia, although the molecular mechanisms have not been fully elucidated. Considering the role of microglia in brain inflammation and the relevant differences among species, the effects of remifentanil were studied on the human microglial C20 cells. The drug was tested at clinically relevant concentrations under basal and inflammatory conditions. In the C20 cells, the expression and secretion of interleukin 6, interleukin 8 and the monocyte chemotactic protein 1 were rapidly induced by a mixture of pro-inflammatory cytokines. This stimulatory effect was sustained up to 24 h. Remifentanil did not exert any toxic effect nor modify the production of these inflammatory mediators, thus suggesting the lack of direct immune modulatory actions on human microglia.

Downloads

Additional Files

Published

2023-02-24

How to Cite

Dello Russo, C., Cappoli, N., Tabolacci, E., Sollazzi, L., Navarra, P., & Aceto, P. (2023). Remifentanil does not affect human microglial immune activation in response to pro-inflammatory cytokines. EXCLI Journal, 22, 295–309. https://doi.org/10.17179/excli2022-5667

Issue

Vol. 22 (2023)

Section

Original articles

Categories

License

Copyright (c) 2023 Cinzia Dello Russo, Natalia Cappoli, Elisabetta Tabolacci, Liliana Sollazzi, Pierluigi Navarra, Paola Aceto

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish in this journal agree to the following terms:

  • The authors keep the copyright and grant the journal the right of first publication under the terms of the Creative Commons Attribution license, CC BY 4.0. This licencse permits unrestricted use, distribution and reproduction in any medium, provided that the original work is properly cited.
  • The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
  • Because the advice and information in this journal are believed to be true and accurate at the time of publication, neither the authors, the editors, nor the publisher accept any legal responsibility for any errors or omissions presented in the publication. The publisher makes no guarantee, express or implied, with respect to the material contained herein.
  • The authors can enter into additional contracts for the non-exclusive distribution of the journal's published version by citing the initial publication in this journal (e.g. publishing in an institutional repository or in a book).

Most read articles by the same author(s)